Valerie Guild was Founder and President of the non-profit organization AIM at Melanoma, and served as a patient advocate on ECOG-ACRIN’s Melanoma Committee for over ten years.
De-escalation is an effort to reduce the intensity of treatment without sacrificing efficacy. This issue covers several de-escalation trials: DECREASE, CompassHER2 pCR, and E3311.
This study is evaluating whether lower doses of chemoradiation will be able to effectively treat early-stage anal squamous cell carcinoma while also decreasing side effects.
The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.